Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
AHK-Cu was tested across 10^-13 to 10^-7 molar concentrations during a 12-day hair-follicle culture experiment
This is laboratory exposure, not topical or injectable human dosing. No controlled systemic administration quantity was identified.
View sourceAn expert-authored topical scalp serum combines 1% AHK-Cu (about 300 mg) with 6% GHK-Cu (about 1.8 g) in a 30 ml base, applied twice daily (nightly first if sensitive) at pH 5.5-7, with an optional weekly 0.5 mm microneedling step; no injectable dose is given
Forum provenance from an authenticated archive with usernames omitted. This is a cosmetic topical formulation, not a systemic or injectable schedule; the AHK-Cu and GHK-Cu amounts are combined in one serum and kept separate rather than interconverted across routes.
View sourceMembers apply the AHK-Cu/GHK-Cu serum to thinning temples and crown with a cosmetic brush, dropper or spray bottle, typically nightly; a hyaluronic-acid base is dampened before use, and retinol or other acids are avoided to prevent degrading the copper peptides
These are technique and handling notes from the same archive rather than a dose-finding schedule. Over-spraying beyond the scalp is linked to faster facial and body hair; the route stays strictly topical apart from one off-protocol injected report that gives no reproducible quantity.
View sourceEvidence summary
A copper-binding tripeptide investigated mainly in laboratory and cosmetic hair or skin contexts. Evidence does not establish a systemic injectable protocol.
Protocol basis
The available evidence is formulation-specific and predominantly preclinical, so no topical-to-injectable conversion is presented.
What remains uncertain
Systemic safety, human pharmacokinetics, dose-response and product equivalence are unknown.
Online research community archive check
The reviewed archive mentions adding AHK-Cu to topical GHK-Cu or hair-serum mixtures but gives no reproducible AHK-Cu mass, concentration, frequency or cycle. That omission is preserved rather than converted into a protocol (raw/peptide-education/pe-ghk-cu.md:1454-1460, :2494-2518).
Community provenance (Peppys)
An authenticated research-forum archive carries an expert-authored topical hair-growth serum that combines 1% AHK-Cu (about 300 mg) with 6% GHK-Cu (about 1.8 g) in a 30 ml base, applied to the scalp twice daily at a slightly acidic pH of 5.5-7, with an optional weekly 0.5 mm microneedling step. It is a cosmetic topical formulation with no injectable dose; a single off-protocol subcutaneous report appears but records no reproducible quantity, and over-spraying beyond the scalp is linked to faster facial and body hair. Usernames are omitted and the figures are logged as community provenance without endorsement, with the two copper-peptide amounts kept separate rather than interconverted across routes. Because the material is topical rather than a reconstituted injectable, no dose planner is presented.